SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combinations treatments for certain cancers.
The post Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition appeared first on MedCity News.
